GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (ASX:RGT) » Definitions » Valuation Rank

Argent Biopharma (ASX:RGT) Valuation Rank


View and export this data going back to 2006. Start your Free Trial

What is Argent Biopharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Argent Biopharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (ASX:RGT) » Definitions » Valuation Rank
Comparable Companies
ASX:EOF ASX:AGH ASX:IVX ASX:EXL ASX:PER ASX:CAN ASX:BP8 ASX:ECS ASX:NXS ASX:LGP ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
RGTLF:USA H5O0:Germany
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Website
https://www.argentbiopharma.com
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.